Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials.

ABSTRACT:

Aims

This post hoc analysis investigates the impact of baseline characteristics on the efficacy and safety of oral semaglutide in a Chinese population with type 2 diabetes.

Materials and methods

Chinese participants from the PIONEER 11 and 12 trials with type 2 diabetes aged ≥18 years were randomised to once-daily oral semaglutide 3, 7, or 14 mg, or placebo (PIONEER 11) or sitagliptin 100 mg (PIONEER 12). Changes from baseline in HbA_1c and body weight at week 26 were analysed in subgroups according to the following baseline characteristics: age, HbA_1c, body mass index, duration of diabetes, and presence of gastrointestinal disease. Adverse events (AEs) by baseline subgroups were also assessed.

Results

In total, 390 (PIONEER 11) and 1084 (PIONEER

SUBMITTER: Ji L 

PROVIDER: S-EPMC12515755 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature